{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=6&sponsor=Celgene", "query": { "sponsor": "Celgene", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 797, "total_pages": 80, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&sponsor=Celgene&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=5&sponsor=Celgene&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T21:14:36.419Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02661815", "title": "A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ricolinostat", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2016-06-15", "completion_date": "2017-07-28", "has_results": true, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02661815" }, { "nct_id": "NCT03174275", "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell", "Oral Cancer", "Oropharynx Cancer", "Larynx Cancer", "Lip Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-12-19", "completion_date": "2027-02-02", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03174275" }, { "nct_id": "NCT03579771", "title": "Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Cholangiocarcinoma", "Stage IB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage II Intrahepatic Cholangiocarcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 30, "start_date": "2018-09-26", "completion_date": "2023-09-16", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579771" }, { "nct_id": "NCT00379912", "title": "Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Erythropoietin", "type": "DRUG" }, { "name": "Azacitidine (Monotherapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Larry Cripe, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2006-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 9, "location_summary": "Galesburg, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 4 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379912" }, { "nct_id": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed Acute Myeloid Leukemia (AML)", "Untreated AML", "AML Arising From Myelodysplastic Syndrome (MDS)", "AML Arising From Antecedent Hematologic Disorder (AHD)", "AML Arising After Exposure to Genotoxic Injury" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-12-31", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632708" }, { "nct_id": "NCT00738361", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-08", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738361" }, { "nct_id": "NCT00842582", "title": "Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2009-02", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 2, "location_summary": "Maywood, Illinois • Winfield, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Winfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00842582" }, { "nct_id": "NCT00995488", "title": "Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "ABI-007 (Abraxane®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2009-10", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-09-11", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00995488" }, { "nct_id": "NCT01757288", "title": "Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER" ], "interventions": [ { "name": "NAB-PACLITAXEL", "type": "DRUG" }, { "name": "PACLITAXEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 98, "start_date": "2013-03-25", "completion_date": "2019-06-03", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 5, "location_summary": "Rochester, New York • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01757288" }, { "nct_id": "NCT00654186", "title": "Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Revlimid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2008-02", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-03-28", "last_synced_at": "2026-10-14T21:14:36.419Z", "location_count": 2, "location_summary": "Niles, Illinois • Park Ridge, Illinois", "locations": [ { "city": "Niles", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654186" } ] }